Evidence map›Paper›PMID 24558496›Full record

ArticlePloS one2014

Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention.

Cécile Gladine, John W Newman, Thierry Durand, Theresa L Pedersen, Jean-Marie Galano, Céline Demougeot, Olivier Berdeaux, Estelle Pujos-Guillot, Andrzej Mazur, Blandine Comte

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03453918 (Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03453918 nacompletednot on this mapstarted 2018, after this paper: background citation

Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.

TypeinterventionalSponsorUniversity Hospital, Clermont-FerrandRan2018 to 2018Enrolled41ConditionsDysmetabolic Iron Overload Syndrome, Genetic Hemochromatosis, Iron Absorption, PolyphenolsArmspolyphenols, Placebo
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 76 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. FInternational journal of molecular sciences · 2023
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. The Various Roles of Fatty Acids.Molecules (Basel, Switzerland) · 2018
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Cécile GladineUMR1019 Unité de Nutrition Humaine (UNH), INRA, CRNH Auvergne, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France.
John W NewmanObesity and Metabolism Research Unit, USDA, ARS, Western Human Nutrition Research Center, Davis, California, United States of America ; Department of Nutrition, University of California, Davis, California, United States of America.
Thierry DurandInstitut des Biomolécules Max Mousseron (IBMM), UMR CNRS 5247, Universités de Montpellier I et II, France, Montpellier, France.
Theresa L PedersenObesity and Metabolism Research Unit, USDA, ARS, Western Human Nutrition Research Center, Davis, California, United States of America.
Jean-Marie GalanoInstitut des Biomolécules Max Mousseron (IBMM), UMR CNRS 5247, Universités de Montpellier I et II, France, Montpellier, France.
Céline DemougeotEA 4267 Fonctions et Dysfonctions epithéliales, University of Franche-Comté, Besançon, France.
Olivier BerdeauxUMR6265 Centre des Sciences du Goût et de l'Alimentation, CNRS, Dijon, France ; UMR1324 Centre des Sciences du Goût et de l'Alimentation, INRA, Dijon, France ; UMR Centre des Sciences du Goût et de l'Alimentation, Université de Bourgogne, Dijon, France.
Estelle Pujos-GuillotUMR1019 Unité de Nutrition Humaine (UNH), INRA, CRNH Auvergne, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France ; UMR 1019, Plateforme d'Exploration du Métabolisme, INRA, Clermont-Ferrand, France.
Andrzej MazurUMR1019 Unité de Nutrition Humaine (UNH), INRA, CRNH Auvergne, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France.
Blandine ComteUMR1019 Unité de Nutrition Humaine (UNH), INRA, CRNH Auvergne, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne · FRCentre National de la Recherche Scientifique · FRInstitut des Biomolécules Max Mousseron · FRUnité de Nutrition Humaine · FRUniversité Clermont Auvergne · FRUniversité de Bourgogne · FRUniversité de franche-comté · FRUniversity of California, Davis · USWestern Human Nutrition Research Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-atherogenic effects of omega 3 fatty acids, namely eicosapentaenoic (EPA) and docosahexaenoic acids (DHA) are well recognized but the impact of dietary intake on bioactive lipid mediator profiles remains unclear. Such a profiling effort may offer novel targets for future studies into the mechanism of action of omega 3 fatty acids. The present study aimed to determine the impact of DHA supplementation on the profiles of polyunsaturated fatty acids (PUFA) oxygenated metabolites and to investigate their contribution to atherosclerosis prevention. A special emphasis was given to the non-enzymatic metabolites knowing the high susceptibility of DHA to free radical-mediated peroxidation and the increased oxidative stress associated with plaque formation. Atherosclerosis prone mice (LDLR(-/-)) received increasing doses of DHA (0, 0.1, 1 or 2% of energy) during 20 weeks leading to a dose-dependent reduction of atherosclerosis (R(2) = 0.97, p = 0.02), triglyceridemia (R(2) = 0.97, p = 0.01) and cholesterolemia (R(2) = 0.96, p<0.01). Targeted lipidomic analyses revealed that both the profiles of EPA and DHA and their corresponding oxygenated metabolites were substantially modulated in plasma and liver. Notably, the hepatic level of F4-neuroprostanes, a specific class of DHA peroxidized metabolites, was strongly correlated with the hepatic DHA level. Moreover, unbiased statistical analysis including correlation analyses, hierarchical cluster and projection to latent structure discriminate analysis revealed that the hepatic level of F4-neuroprostanes was the variable most negatively correlated with the plaque extent (p<0.001) and along with plasma EPA-derived diols was an important mathematical positive predictor of atherosclerosis prevention. Thus, oxygenated n-3 PUFAs, and F4-neuroprostanes in particular, are potential biomarkers of DHA-associated atherosclerosis prevention. While these may contribute to the anti-atherogenic effects of DHA, further in vitro investigations are needed to confirm such a contention and to decipher the molecular mechanisms of action.

Indexed as

Analysis of VarianceAnimalsAtherosclerosisBiomarkersBlood PressureChromatography, LiquidCluster AnalysisDocosahexaenoic AcidsDose-Response Relationship, DrugFatty Acids, UnsaturatedGas Chromatography-Mass SpectrometryHeart RateLipid MetabolismLiverMiceMice, KnockoutBiomarkersDocosahexaenoic AcidsFatty Acids, UnsaturatedNeuroprostanesReceptors, LDL

Identifiers

PMID24558496
PMCPMC3928438
OpenAlexW2013671349

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.